Sign In
Buy DNA
$7.89
-0.110 (-1.38%)
At Close: Jun 12, 2026
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
04:10pm, Tuesday, 17'th Jun 2025
President and COO Judy Murrah Appointed New Chairperson of the Board of Directors and CEO STONY BROOK, NY / ACCESS Newswire / June 17, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or
Clinical Data Highlight PlaCCine's Six-Month Durability, Temperature Stability, and Manufacturing Advantages Over mRNA Vaccines
Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August
09:00am, Monday, 16'th Jun 2025
STONY BROOK, NY / ACCESS Newswire / June 16, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will resu
23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm
05:07pm, Friday, 13'th Jun 2025
23andMe filed for bankruptcy in March, seeking to sell its business at auction after a decline in consumer demand and a 2023 data breachthat exposed sensitive genetic and personal information of mill
23andMe's founder Anne Wojcicki wins bid for DNA testing firm
04:30pm, Friday, 13'th Jun 2025
Anne Wojcicki is set to regain control of 23andMe after a nonprofit she controls topped Regeneron's bid for the DNA-testing company.
Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol
Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival - highlighting Telomir-1's pot
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025
08:00am, Thursday, 29'th May 2025
STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effec
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis
09:00am, Wednesday, 28'th May 2025
SAN DIEGO--(BUSINESS WIRE)--Telesis Bio Inc. (OTCMKTS: TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundr
Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer
04:05pm, Wednesday, 21'st May 2025
BOSTON , May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dm
23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.
09:45am, Monday, 19'th May 2025
Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, both companies said. 23andMe filed for Chapter 11 bankruptcy earlier this year.
23andMe sells its most valuable asset. Regeneron promises keep your DNA private.
08:40am, Monday, 19'th May 2025
Regeneron said it will continue uninterrupted service of 23andMe's consumer genome services — such as connecting with living relatives with shared DNA — after its purchase closes as expected in th
Applied DNA Reports Second Quarter Fiscal 2025 Financial Results
04:05pm, Thursday, 15'th May 2025
- Therapeutic DNA Production Services Segment (LineaRx) Revenues Up 44% Y/Y, Contributing to a 6% Increase in Total Revenues - - Intra-Quarter Investor Conference Call and Webcast Scheduled for June
Company's PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
11:30am, Wednesday, 14'th May 2025
STONY BROOK, NY / ACCESS Newswire / May 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, will relea
